Tim Lu takes Sen­ti and its gene cir­cuit tech pub­lic in $296M deal rid­ing on Omid Farokhzad's SPAC

Omid Farokhzad didn’t have to trav­el far to find a pri­vate biotech he want­ed to take pub­lic with his $200 mil­lion blank-check com­pa­ny.

Sen­ti Bio — the syn­thet­ic bi­ol­o­gy play launched and now helmed by MIT whiz Tim Lu — will be merg­ing with Farokhzad’s Dy­nam­ics Spe­cial Pur­pose Corp., the com­pa­nies an­nounced Mon­day morn­ing, in a deal set to de­liv­er $296 mil­lion in gross pro­ceeds.

Us­ing a gene cir­cuit tech­nol­o­gy plat­form out of Lu’s lab, Sen­ti promis­es to pro­gram “sense-com­pute-re­spond” ca­pa­bil­i­ties in­to cell and gene ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER